Compare WYETH LTD with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs TORRENT PHARMA - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD TORRENT PHARMA WYETH LTD/
TORRENT PHARMA
 
P/E (TTM) x 27.7 55.1 50.3% View Chart
P/BV x 5.3 6.6 81.0% View Chart
Dividend Yield % 1.3 0.8 164.0%  

Financials

 WYETH LTD   TORRENT PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
TORRENT PHARMA
Mar-18
WYETH LTD/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0441,550 67.4%   
Low Rs8181,144 71.5%   
Sales per share (Unadj.) Rs298.6354.7 84.2%  
Earnings per share (Unadj.) Rs57.240.1 142.8%  
Cash flow per share (Unadj.) Rs58.464.2 91.0%  
Dividends per share (Unadj.) Rs17.0014.00 121.4%  
Dividend yield (eoy) %1.81.0 175.6%  
Book value per share (Unadj.) Rs249.5273.1 91.3%  
Shares outstanding (eoy) m22.72169.22 13.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.13.8 82.1%   
Avg P/E ratio x16.333.6 48.4%  
P/CF ratio (eoy) x15.921.0 76.0%  
Price / Book Value ratio x3.74.9 75.7%  
Dividend payout %29.734.9 85.0%   
Avg Mkt Cap Rs m21,157227,897 9.3%   
No. of employees `0000.514.7 3.3%   
Total wages/salary Rs m40011,353 3.5%   
Avg. sales/employee Rs Th13,787.44,083.0 337.7%   
Avg. wages/employee Rs Th813.0772.3 105.3%   
Avg. net profit/employee Rs Th2,643.3461.3 573.0%   
INCOME DATA
Net Sales Rs m6,78360,021 11.3%  
Other income Rs m3532,988 11.8%   
Total revenues Rs m7,13663,009 11.3%   
Gross profit Rs m1,61713,493 12.0%  
Depreciation Rs m274,086 0.7%   
Interest Rs m63,085 0.2%   
Profit before tax Rs m1,9389,310 20.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6322,529 25.0%   
Profit after tax Rs m1,3016,781 19.2%  
Gross profit margin %23.822.5 106.1%  
Effective tax rate %32.627.2 120.1%   
Net profit margin %19.211.3 169.7%  
BALANCE SHEET DATA
Current assets Rs m6,98452,623 13.3%   
Current liabilities Rs m2,05652,022 4.0%   
Net working cap to sales %72.61.0 7,249.2%  
Current ratio x3.41.0 335.8%  
Inventory Days Days99120 83.0%  
Debtors Days Days2476 31.4%  
Net fixed assets Rs m24485,016 0.3%   
Share capital Rs m227846 26.8%   
"Free" reserves Rs m5,44145,376 12.0%   
Net worth Rs m5,66846,222 12.3%   
Long term debt Rs m2541,115 0.1%   
Total assets Rs m7,901142,432 5.5%  
Interest coverage x353.34.0 8,793.5%   
Debt to equity ratio x00.9 0.5%  
Sales to assets ratio x0.90.4 203.7%   
Return on assets %16.56.9 238.6%  
Return on equity %22.914.7 156.4%  
Return on capital %34.014.2 239.9%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1514,580 0.1%   
Fx outflow Rs m2,6773,600 74.4%   
Net fx Rs m-2,66210,980 -24.2%   
CASH FLOW
From Operations Rs m9238,942 10.3%  
From Investments Rs m317-47,070 -0.7%  
From Financial Activity Rs m-48134,174 -1.4%  
Net Cashflow Rs m759-3,655 -20.8%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 7.0 161.0%  
FIIs % 7.2 12.6 57.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 8.8 345.5%  
Shareholders   21,978 26,511 82.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare WYETH LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Generate Alpha over the Next Decade(Profit Hunter)

Oct 29, 2019

Here's your chance benefit from a safe approach to making money in stock markets .

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS